Redcare Pharmacy raised guidance. Redcare Pharmacy stock gains 1.44 percent

Published on 10/09/2026 at 14:32 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

German Rx revenue grew 56.00 percent in Q3 2026. Redcare Pharmacy stock costs EUR 73.75 on October 9, 2026 in trading versus EUR 72.70.

Key points in brief

Redcare Pharmacy raised full-year 2026 revenue-growth guidance to 16.00% to 18.00% on September 28, 2026.
German prescription-drug revenue grew 56.00% year over year in the third quarter of 2026.
The stock was trading at EUR 73.75 at Lang & Schwarz on October 9, 2026, up 1.44% versus EUR 72.70.
The next quarterly statement is scheduled for October 29, 2026, followed by a Baader Bank investor event on November 2, 2026.

Isometrisches 3D-Diagramm der Wertschöpfungskette einer Online-Apotheke bis zur Lieferung — Redcare Pharmacy (Shop Apoth), ISIN NL0012044747, visualisiert 3D-Diagramm der Wertschöpfungskette vom Lager bis Lieferung, Illustration mit AI erstellt.

Redcare Pharmacy (ISIN NL0012044747) had raised its full-year 2026 revenue-growth guidance to 16.00% to 18.00% on September 28, 2026, while the stock was trading at EUR 73.75 at Lang & Schwarz on October 9, 2026, up 1.44% versus the EUR 72.70 prior close. According to Redcare Pharmacy, German prescription-drug revenue grew 56.00% year over year in the third quarter of 2026.

Guidance moves higher

The September 28 guidance update lifted the expected German prescription-drug revenue range for full-year 2026 to EUR 730.0 million to EUR 760.0 million from EUR 680.0 million to EUR 720.0 million. The company also kept non-prescription growth guidance at 10.00% to 12.00% and adjusted EBITDA margin guidance at 2.50% to 3.00%, according to Redcare Pharmacy.

The preliminary third-quarter prescription trend gives the upgrade its operating basis: September growth reached 51.00% year over year, while the German prescription business rose 56.00% in the quarter. The e-prescription customer Net Promoter Score also reached 80 in August, 6 points higher than a year earlier, the company said in the same September 28 release.

What does the margin mean?

Profitability is the key counterweight to the sales momentum. In the second quarter of 2026, revenue rose 20.00% year over year to EUR 853.0 million, while adjusted EBITDA increased 63.00% to EUR 29.6 million and the adjusted EBITDA margin reached 3.50%, according to Stockhouse. The full-year margin guidance of 2.50% to 3.00% therefore sits below the second-quarter margin, leaving execution and the product mix as the next test.

Three milestones frame the story

On July 29, 2026, Redcare reported second-quarter revenue growth of 20.00% and a 3.50% adjusted EBITDA margin, according to Yahoo Finance. On September 15, 2026, CardLink approval was extended through March 31, 2028, according to EQS News. On September 28, 2026, the company raised its full-year revenue-growth range to 16.00% to 18.00%, making the guidance revision the latest of the three milestones.

Upcoming dates and trading

Redcare Pharmacy is scheduled to publish its third-quarter 2026 interim statement on October 29, 2026, followed by a Baader Bank virtual investor event on November 2, 2026, according to the company's published calendar. The stock's EUR 30.20 to EUR 90.05 52-week range places the current EUR 73.75 quote above its yearly midpoint, while the EUR 1.5 billion market capitalization gives the guidance revision a relatively small-capitalization setting.

At Lang & Schwarz, Redcare Pharmacy stock was trading at EUR 73.75 on October 9, 2026 at 2:29 p.m. CEST, up 1.44% versus the prior close of EUR 72.70 on October 8, 2026. The further course of trading is shown by the continuously updated real-time quote of Redcare Pharmacy stock.